Cell and Gene Therapy Bioanalytical Testing Services Market Report Scope and Overview:

The Cell and Gene Therapy Bioanalytical Testing Services Market was valued at USD 612.50 Million in 2025 and is projected to reach USD 1,347.03 Million by 2035, growing at a CAGR of 8.20% during the forecast period.

The Cell and Gene Therapy Bioanalytical Testing Services Market continues to expand as the volume of clinical-stage cell and gene therapy programs rises and sponsors increasingly route potency assay development, pharmacokinetic and pharmacodynamic characterization, and vector or transgene quantification work to specialized outside laboratories rather than building this capability internally. Regulatory agencies are placing growing emphasis on robust, product-specific potency and biodistribution assays ahead of pivotal trials, a requirement that few sponsors, particularly smaller cell and gene therapy developers, can meet without an experienced bioanalytical partner. Investment is concentrating around flow cytometry, digital PCR, and cell-based potency platforms capable of handling the variability inherent to living-cell and viral-vector products, while growing commercial approval volume is pushing testing partners to build out late-stage and commercial-release capacity alongside their existing early-phase development work. Sponsors are also placing greater weight on a prospective testing partner's cross-regional regulatory experience, reflecting the increasingly global nature of advanced therapy development and the need to generate bioanalytical data acceptable to multiple health authorities simultaneously.

⮞SGS completed its acquisition of CMIC, a Chicago-based bioanalytical testing provider operating a 27,000-square-foot GLP-compliant site, in June 2026, extending its North American pre-clinical and clinical bioanalytical footprint for advanced therapy sponsors.

U.S. Cell and Gene Therapy Bioanalytical Testing Services Market Outlook

The U.S. Cell and Gene Therapy Bioanalytical Testing Services Market was valued at approximately USD 233.64 Million in 2025 and is projected to reach USD 520.99 Million by 2035, expanding at a CAGR of 8.35% over the forecast period.

Demand across the United States continued to be shaped by the country's dense concentration of clinical-stage cell and gene therapy sponsors, a deep base of academic and biotech innovation hubs, and an established regulatory pathway that places significant weight on sponsor-specific potency and biodistribution data ahead of pivotal and commercial-stage filings. Sponsors advancing oncology and rare genetic disease programs continued to depend on contract bioanalytical partners for assay development, validation, and sample analysis across both clinical and non-clinical study phases, particularly given the specialized equipment and expertise such testing requires. Growing capacity investment across established biotech clusters, including North Carolina's Research Triangle region, continued reinforcing the country's position as the leading hub for cell and gene therapy bioanalytical capacity, with several providers expanding dedicated advanced-therapy testing suites during the year. Growing recognition of the strategic value of domestic testing capacity is also encouraging longer-duration capacity reservation agreements between sponsors and established U.S. bioanalytical partners.

⮞Labcorp announced in August 2025 that it had tripled capacity at its cell and gene therapy preclinical testing facility in Burlington, North Carolina, adding dedicated ocular, stereotaxic, and MRI-guided surgery suites to support advanced therapy development programs.

By Test Type: Pharmacokinetics Leads, Bioavailability and Bioequivalence Studies Grow Fastest

The Pharmacokinetics segment dominated the market as sponsors across nearly every cell and gene therapy modality require detailed exposure and persistence data to support dose selection and regulatory filings. The breadth of specialized assay formats needed to track living-cell products and viral vectors within the body, often requiring custom method development per product, keeps this work concentrated with experienced bioanalytical partners that already hold the relevant platform expertise and regulatory familiarity with novel modality assessment.

The Bioavailability and Bioequivalence Studies segment is growing fastest as an expanding set of next-generation gene therapy candidates requires comparative exposure data across formulation or delivery-route variants during development. Sponsors increasingly engage contract partners early to design these comparative study programs, reflecting the technical complexity of applying traditional bioequivalence frameworks to living-cell and viral-vector products.

By Product Type: Cell Therapy Dominates, Gene-Modified Cell Therapy Grows Fastest

The Cell Therapy segment dominated the market, supported by the longer clinical history and larger commercial base of approved cell therapy products relative to newer modalities, which has allowed testing partners to build deep, standardized assay libraries specific to this category. Sponsors advancing both autologous and allogeneic cell therapy programs continued to rely on this accumulated assay expertise to accelerate their own development timelines.

The Gene-Modified Cell Therapy segment is the fastest growing as chimeric antigen receptor and T-cell receptor-engineered therapies continue advancing through clinical development in growing numbers. These products require combined cellular and genetic characterization, including vector copy number and transgene expression analysis, pushing sponsors toward partners capable of integrating both disciplines within a single testing program.

By Stage: Clinical Dominates, Non-Clinical Grows Fastest

The Clinical segment dominated the market, reflecting the sheer volume of ongoing clinical-stage cell and gene therapy programs relative to earlier discovery-stage work, and the repeated, high-frequency testing that clinical trials require across multiple dosing cohorts and follow-up visits. Sponsors running multi-site clinical trials continued to favor partners with proven clinical-sample logistics and high-throughput assay capacity.

The Non-Clinical segment is the fastest growing as an expanding pipeline of preclinical cell and gene therapy candidates requires early biodistribution, toxicology-supportive, and proof-of-concept bioanalytical data ahead of investigational new drug filings. Sponsors are increasingly engaging testing partners earlier in development to de-risk later clinical-stage assay performance.

By Indication: Oncology Leads, Rare Genetic Diseases Grow Fastest

The Oncology segment dominated the market, reflecting the sustained volume of chimeric antigen receptor T-cell and other engineered cell therapy programs advancing through clinical development for hematologic and solid tumor indications. The specialized potency and immune-function assays such programs require have made established bioanalytical partners the default choice for sponsors in this indication category.

The Rare Genetic Diseases segment is the fastest growing as an expanding pipeline of adeno-associated virus-based gene therapies targeting rare monogenic conditions advances toward pivotal and commercial stages. Sponsors in this category, often smaller and resource-constrained, are increasingly dependent on contract bioanalytical partners for the specialized vector biodistribution and immunogenicity testing these programs require. The relatively small patient populations and bespoke manufacturing processes typical of rare genetic disease programs further reinforce reliance on experienced outside partners rather than internal capability built for a single product.

Regional Analysis

North America Cell and Gene Therapy Bioanalytical Testing Services Market Insights

North America dominated the Cell and Gene Therapy Bioanalytical Testing Services Market with the largest revenue share of approximately 44.20% in 2025, supported by the region's dense concentration of clinical-stage cell and gene therapy sponsors, deep venture and public capital access for advanced therapy developers, and an established base of bioanalytical testing partners offering potency, pharmacokinetic, and vector characterization capability across the full development lifecycle.

The United States accounted for the substantial majority of regional revenue, anchored by concentrated biotech innovation clusters in the Northeast, California, and North Carolina's Research Triangle region, where several testing partners expanded dedicated advanced-therapy laboratory capacity during 2025. Canada continued contributing a smaller but steady share of regional demand, supported by academic cell and gene therapy research centers and a growing base of early-stage developers.

Europe Cell and Gene Therapy Bioanalytical Testing Services Market Insights

Europe held a meaningful share of global revenue, supported by strong national investment in advanced therapy medicinal product research infrastructure, a coordinated regulatory framework for cell and gene therapy evaluation, and an established base of contract bioanalytical laboratories serving both domestic and cross-border sponsors advancing novel modality programs.

Germany continued to lead regional demand at roughly 22.40% of European revenue, supported by its concentration of advanced therapy manufacturing and testing infrastructure, while the United Kingdom and Switzerland continued contributing significant specialized bioanalytical capacity for gene therapy characterization work.

Asia Pacific Cell and Gene Therapy Bioanalytical Testing Services Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 10.60% from 2026 to 2035, driven by a rapidly expanding clinical-stage cell and gene therapy pipeline across China, Japan, and South Korea, alongside rising regional investment in bioanalytical testing capacity to support both domestic sponsors and multinational programs seeking to diversify testing capacity outside Western hubs. Regional governments are also funding advanced therapy manufacturing and testing infrastructure as part of broader biotechnology industrial policy, reinforcing this growth trajectory.

China held a substantial share of regional revenue, supported by a rapidly growing base of domestic cell and gene therapy developers and government-backed investment in advanced therapy infrastructure, while Japan and South Korea continued strengthening specialized testing capability tied to their established regenerative medicine regulatory pathways.

MEA and Latin America Cell and Gene Therapy Bioanalytical Testing Services Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by gradually expanding clinical trial activity for advanced therapies, rising government interest in regenerative medicine research infrastructure, and growing willingness among global sponsors to qualify testing partners outside traditional North American and European hubs for selected non-clinical study components.

Saudi Arabia led Middle East and Africa demand, supported by the country's broader healthcare research investment initiatives, while Brazil led Latin America, benefiting from an expanding clinical trial base for cell and gene therapy programs and growing academic research capacity in advanced therapy development. Both sub-regions continued to rely primarily on North American and European partners for the most complex characterization work, reserving local capacity for routine release and stability testing.

Market Dynamics

Growth Drivers: Rising Clinical-Stage Pipeline and Regulatory Emphasis on Potency Testing

The industry is driven by the expanding volume of clinical-stage cell and gene therapy programs advancing toward pivotal and commercial-stage filings, each requiring extensive, product-specific bioanalytical characterization that few sponsors can economically build and validate internally given the limited duration and uncertain outcome of any single development program.

Rising regulatory emphasis on robust, product-specific potency and biodistribution assays continues supporting demand for specialized testing partners, as agencies increasingly expect sponsors to demonstrate assay validity and reproducibility well ahead of pivotal trial initiation, a standard that experienced contract bioanalytical laboratories are better positioned to meet than in-house teams assembled for a single program.

Restraints: Assay Development Complexity and Limited Specialist Capacity

Persistent complexity in developing and validating product-specific potency and characterization assays continues posing a restraint, with each new cell or gene therapy modality often requiring a bespoke assay approach that cannot be readily adapted from existing platforms, extending development timelines and raising costs for both sponsors and testing partners alike.

Limited specialist capacity among qualified bioanalytical testing providers continues constraining throughput, particularly for advanced flow cytometry and molecular characterization work, with sponsors sometimes facing extended queues for assay development slots during periods of elevated clinical trial activity concentrated among a small number of experienced providers.

Opportunities: Expanding Non-Clinical Demand and Emerging Market Capacity Growth

Rising non-clinical and early discovery-stage testing demand represents a significant opportunity for bioanalytical partners able to support sponsors earlier in development, as more developers seek to de-risk later-stage assay performance by engaging testing partners well ahead of investigational new drug submission.

Expanding capacity investment across Asia Pacific and other emerging research hubs offers a second substantial opportunity, as multinational sponsors increasingly qualify additional regional testing partners to diversify capacity and reduce reliance on a concentrated set of North American and European providers. This shift is creating room for a broader group of regional laboratories to win qualification from sponsors that previously concentrated testing with a small set of established partners.

Cell and Gene Therapy Bioanalytical Testing Services Market key players are:

• BioAgilytix Labs

• KCAS Bioanalytical Services

• Labcorp Drug Development

• IQVIA Inc.

• Charles River Laboratories

• Pharmaron

• Syneos Health

• SGS SA

• Intertek Group plc

• Eurofins Scientific

• Pharmaceutical Product Development, LLC

• Alcami Corporation

• Solvias AG

• Frontage Laboratories

• Celerion

• Cytovance Biologics

• WuXi AppTec

• Almac Group

• Nelson Labs

• National Resilience, Inc.

Cell and Gene Therapy Bioanalytical Testing Services Market Report Scope: